Saba Shaikh, MD, talks with Komal Jhaveri, MD, about the results of the ASCENT-07 study, which demonstrated that patients with HR-positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy.
Estimated Read Time:
1 minute
SABCS Snippets: Results from the Phase III ASCENT-07 Trial
Share
Recent Posts
-
December 15, 2025
-
December 15, 2025
-
FDA session offers closer look at approval process for HR-positive metastatic breast cancer therapies
December 15, 2025 -
December 15, 2025
